The „Jean-Uhrmacher-Institute for Clinical ENT-Research (JUI)“ was founded in 2002 and is situated close to the University Hospital Cologne.
As an institute associated with the University of Cologne and in cooperation with the ENT-University Hospital and further partners of the University of Cologne, JUI conducts research with regard to the diagnosis, therapy and rehabilitation of ear, nose and throat diseases. Specifically, inflammatory and carciogenic processes (Oncology) as well as communication disorders (Audiology) including rehabilitation with modern hearing systems (Cochlear Implants, Cochlear Implant Centrum Köln – CIK) are focussed.
The Jean-Uhrmacher-Institute is supported by the Jean-Uhrmacher-Foundation, which was established in 1978 by Mrs. Hildegard Uhrmacher to help investigate the causes and consequences of ENT-related diseases and develop appropriate therapies and rehabilitation measures.
The Jean-Uhrmacher-Institute (JUI) is a modern research institution, that offers excellent opportunities for interdisciplinary science in the area of clinically oriented ENT research and particularly promotes young scientists.
Based in Cologne as a foundation under civil law, the Jean-Uhrmacher-Foundation has defined its tasks and objectives for the study of diseases in Otorhinolaryngology. For this purpose, research projects are carried out and supported in cooperation with the ear, nose and throat clinic of the University of Cologne and other academic and university partners.
The focus of our research is the perception of speech under consideration of auditory, technical, linguistic, and neuropsychological aspects. It aims at expanding knowledge regarding diagnosis and rehabilitation of communication disorders and to promote clinically appicable procedures
Approximately 600.000 new cases of head and neck squamous cell carcinoma (HNSCC) have been estimated to occur worldwide in 2011, ranking them in sixth position of all carcinomas 1-3. Risk factors for the development of HNSCC include environmental factors, excessive tobacco- and alcohol use, as well as human papillomavirus (HPV) infections.